Is RELMADA THERAPEUTICS, INC. (RLMD) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 13.8% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 13.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 98.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 13.8% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 98.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -94.0% | |
| Return on Assets (ROA) | -50.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$52M |
| Free Cash Flow | -$52M |
| Current Ratio | 14.6 |
| Total Assets | $46M |
Price & Trading
| Last Close | $6.54 |
| 50-Day MA | $4.75 |
| 200-Day MA | $2.80 |
| Avg Volume | 1.5M |
| Beta | 0.7 |
|
52-Week Range
$0.24
| |
About RELMADA THERAPEUTICS, INC. (RLMD)
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is RELMADA THERAPEUTICS, INC. (RLMD) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), RELMADA THERAPEUTICS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is RELMADA THERAPEUTICS, INC.'s debt ratio?
RELMADA THERAPEUTICS, INC.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are RELMADA THERAPEUTICS, INC.'s key financial metrics?
RELMADA THERAPEUTICS, INC. has a market capitalization of $674M. Return on equity stands at -94.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.